Highlights

  • Optiscan and Mayo Clinic have reached the two-year milestone of their Know-How Agreement.
  • All major engineering milestones and development objectives for the collaboration have been completed.
  • The agreement has been extended until 12 August 2026 to support strategic, clinical and commercial planning.
  • Development work has focused on integrating Optiscan's imaging technology into robotic-assisted surgical workflows.
  • The collaboration continues to progress toward preclinical testing and future development activities.

Optiscan Imaging Ltd (ASX:OIL) has announced that its collaboration with Mayo Clinic has reached an important two-year milestone, with both organisations continuing to advance the development of a digital endomicroscopic imaging system designed for use in robotic-assisted surgery. The update highlighted the completion of all major engineering objectives under the agreement and confirmed that the collaboration will continue following a three-month extension to support future planning activities.

Investors appeared to respond favourably to the announcement, with Optiscan shares rising 6.38% to AUD 0.12 during the afternoon session on 1 June 2026. While the stock remains down 3.85% over the past 12 months, the market reaction suggests investors welcomed the continued progress achieved under the company's relationship with one of the world's most recognised healthcare institutions.

Optiscan is a commercial-stage medical technology company focused on digital pathology and precision surgery solutions. The company has developed miniature endomicroscopy technology capable of producing real-time microscopic imaging at cellular resolution, supporting applications across surgery, diagnostics and life sciences. In recent years, Optiscan has increasingly focused on expanding the use of its technology into robotic-assisted surgical environments, a strategy that sits at the centre of its collaboration with Mayo Clinic.

Two Years of Development Progress Achieved

The latest announcement marks two years since Optiscan entered into its Know-How Agreement with Mayo Clinic.

Over that period, both organisations have worked together to adapt Optiscan's imaging technology for use within robotic surgery settings. According to the company, the collaboration has successfully completed all planned engineering milestones and development objectives scheduled under the agreement.

The work has focused on creating a robotic-enabled confocal imaging platform capable of providing surgeons with microscopic visualisation during procedures.

Throughout the development process, the parties completed concept design work, feasibility assessments, technical reviews, prototype development and integration testing activities.

The successful completion of these milestones represents a significant stage in the ongoing development of the technology and provides a foundation for future clinical and commercial planning.

To support those next steps, the agreement has now been extended until 12 August 2026, allowing both organisations additional time to evaluate strategic, clinical and commercial pathways as development activities continue.

Focus on Robotic Surgery Integration

A major objective of the collaboration has been determining how Optiscan's imaging technology could be integrated into robotic-assisted surgical procedures.

According to the company, Mayo Clinic surgeons worked alongside Optiscan's engineering team to evaluate how the imaging platform could fit into robotic-assisted breast surgery workflows.

The assessment involved examining both hardware and software requirements needed to support compatibility with robotic surgery systems.

The broader goal is to enable real-time cellular-level imaging during robotic procedures. Such imaging could provide surgeons with immediate visual information while operations are underway, potentially assisting clinical decision-making within the surgical environment.

The collaboration has explored how Optiscan's imaging capabilities may be incorporated into existing robotic surgical workflows rather than requiring entirely new operating systems.

Compatibility assessments have also examined how imaging data could be integrated into robotic visualisation systems using Picture-in-Picture protocols and established surgeon interfaces.

These evaluations form an important component of the broader development pathway as the technology progresses toward future testing phases.

Engineering Milestones Lay Groundwork for Next Phase

Optiscan noted that the collaboration has now advanced beyond initial development activities and has successfully delivered all planned engineering outcomes outlined within the agreement.

Among the completed milestones were system requirement reviews, prototype development programmes, feasibility assessments and integration testing exercises.

The company stated that development efforts have progressively moved the platform from concept and prototype stages toward future preclinical testing activities.

The next phase is expected to involve planning for additional preclinical programmes and clinical protocols, although these activities will occur outside the existing agreement and remain subject to standard regulatory, ethics and study approval requirements.

Robotic-assisted breast surgery has been identified as the first candidate application area for future evaluation.

The extension of the agreement allows both organisations to focus on planning these future stages while also considering commercial opportunities and broader strategic objectives.

Why the Mayo Clinic Relationship Matters

Mayo Clinic is widely regarded as one of the most recognised healthcare organisations globally and operates one of the largest integrated not-for-profit medical group practices in the world.

For Optiscan, the relationship provides access to clinical expertise within robotic surgery and supports the practical evaluation of its technology in real-world surgical settings.

The collaboration combines Mayo Clinic's experience in surgical innovation with Optiscan's expertise in real-time microscopic imaging.

Management believes this combination has helped accelerate development of a robotic-compatible imaging solution designed to support surgical precision and intraoperative decision-making.

The company also indicated that the relationship contributes to its broader expansion strategy within the United States, where robotic surgery continues to represent a large and growing healthcare segment.

Importantly, Optiscan has maintained a flexible development approach throughout the project. Rather than designing the platform around a single robotic system provider, the company has sought to preserve compatibility across multiple robotic platforms.

This strategy may allow greater flexibility as future commercial opportunities are evaluated.

Commercial Opportunity Remains a Key Focus

Beyond technical development, the company highlighted the commercial significance of the robotic surgery market.

According to Optiscan, the United States remains the largest robotic surgery market globally and accounts for more than half of worldwide robotic surgery Revenue.

The company noted that the U.S. robotic surgery market is currently valued at approximately US$7 billion to US$7.5 billion and continues to expand at double-digit growth rates.

Within this environment, Optiscan sees an opportunity to position its imaging technology as a complementary tool capable of enhancing surgical visualisation and workflow efficiency.

Management stated that progress achieved under the Mayo Clinic collaboration reinforces the adaptability of the company's imaging platform across a variety of clinical settings.

The company also believes the development work completed to date supports its broader strategy of commercialising imaging technologies across multiple medical applications.

As robotic-assisted surgery continues to evolve, Optiscan is seeking to establish a presence within a Market Segment that aligns with its expertise in real-time microscopic imaging and digital pathology solutions.

Technology Designed to Support Surgical Decision-Making

The collaboration has focused on developing technology capable of providing high-resolution microscopic visualisation during robotic-assisted procedures.

The platform under development is intended to support surgeons by delivering live tissue imaging while surgery is taking place.

Optiscan believes this capability could assist intraoperative decision-making by providing additional visual information during procedures.

The company has repeatedly emphasised the potential role of real-time imaging in supporting precision surgery, an area that continues to attract interest across healthcare and medical technology sectors.

According to management, the development work completed over the past two years demonstrates the adaptability of Optiscan's technology and its potential applicability across a broad range of future clinical uses.

The company also noted that integrating imaging technology with robotic systems may offer additional stability and precision compared with traditional handheld approaches.

What This Means for Investors

Optiscan's latest update centres on continued progress within its collaboration with Mayo Clinic, one of the company's most prominent strategic relationships.

The completion of all major engineering milestones, successful integration assessments and extension of the agreement provide evidence that development activities continue to advance. The project has now moved beyond initial concept stages and is progressing toward future preclinical testing and broader planning activities.

The favourable market reaction on 1 June 2026 suggests investors welcomed confirmation that the collaboration remains active and continues to generate development outcomes.

With further preclinical work, clinical planning and commercial evaluations expected to follow, investors are likely to monitor future updates as Optiscan advances its robotic surgery imaging platform and broader precision surgery strategy.